Myovant Sciences Stock Forecast, Price & News

Myovant Sciences' stock was trading at $8.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MYOV stock has increased by 151.1% and is now trading at $21.85.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Myovant Sciences.

Wall Street analysts have given Myovant Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Myovant Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Myovant Sciences is scheduled to release its next quarterly earnings announcement on Monday, February 8th 2021.
View our earnings forecast for Myovant Sciences.

Myovant Sciences Ltd. (NYSE:MYOV) announced its earnings results on Thursday, November, 12th. The company reported ($0.75) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.78) by $0.03.
View Myovant Sciences' earnings history.

5 analysts have issued 1-year target prices for Myovant Sciences' stock. Their forecasts range from $20.00 to $55.00. On average, they anticipate Myovant Sciences' stock price to reach $32.25 in the next twelve months. This suggests a possible upside of 47.6% from the stock's current price.
View analysts' price targets for Myovant Sciences.

Myovant Sciences saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 4,320,000 shares, an increase of 116.0% from the September 30th total of 2,000,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is presently 3.7 days. Approximately 13.6% of the company's stock are sold short.
View Myovant Sciences' Short Interest.

Some companies that are related to Myovant Sciences include Jazz Pharmaceuticals (JAZZ), Galapagos (GLPG), Ultragenyx Pharmaceutical (RARE), Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC), Perrigo (PRGO), Zai Lab (ZLAB), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), Allakos (ALLK), Biohaven Pharmaceutical (BHVN) and Reata Pharmaceuticals (RETA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL).

(MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Myovant Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Lord Abbett & CO. LLC (2.02%), Victory Capital Management Inc. (1.98%), PFM Health Sciences LP (0.69%), Candriam Luxembourg S.C.A. (0.54%), Rhenman & Partners Asset Management AB (0.42%) and Platinum Investment Management Ltd. (0.28%). Company insiders that own Myovant Sciences stock include Andrew Lo, Chemical Co Ltd Sumitomo, Ferreira Juan Camilo Arjona, Frank Karbe, Kathleen Sebelius, Kim Sablich, Matthew Lang and Sciences Ltd Roivant.
View institutional ownership trends for Myovant Sciences.

MYOV stock was sold by a variety of institutional investors in the last quarter, including Connor Clark & Lunn Investment Management Ltd., Victory Capital Management Inc., Platinum Investment Management Ltd., UBS Asset Management Americas Inc., Thrivent Financial for Lutherans, Ardsley Advisory Partners LP, Cambridge Investment Research Advisors Inc., and Cubist Systematic Strategies LLC. Company insiders that have sold Myovant Sciences company stock in the last year include Ferreira Juan Camilo Arjona, Frank Karbe, Kim Sablich, and Matthew Lang.
View insider buying and selling activity for Myovant Sciences.

MYOV stock was acquired by a variety of institutional investors in the last quarter, including PFM Health Sciences LP, Lord Abbett & CO. LLC, Candriam Luxembourg S.C.A., Rhenman & Partners Asset Management AB, Morgan Stanley, Evolution Wealth Advisors LLC, Engineers Gate Manager LP, and Twinbeech Capital LP. Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Chemical Co Ltd Sumitomo, Frank Karbe, Kathleen Sebelius, and Sciences Ltd Roivant.
View insider buying and selling activity for Myovant Sciences.

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MYOV stock can currently be purchased for approximately $21.85.

Myovant Sciences has a market capitalization of $1.98 billion. The company earns $-288,990,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Myovant Sciences employs 214 workers across the globe.

The official website for Myovant Sciences is www.myovant.com.

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3351 or via email at [email protected]